Literature DB >> 34019960

Cancer-associated fibroblasts in non-small cell lung cancer: Recent advances and future perspectives.

Hongfang Zhang1, Hong Jiang2, Lucheng Zhu3, Jiawei Li4, Shenglin Ma5.   

Abstract

Non-small cell lung cancer (NSCLC) constitutes the majority of lung cancer, which is the leading cause of cancer-related deaths in the world. Nearly 70% of NSCLC patients were diagnosed at advanced stage with only 15% of five-year survival rate. Cancer-associated fibroblasts (CAFs) are the major component of tumor microenvironment and account for almost 70% of the cells in tumor tissues. By the crosstalk with cancer cells, CAFs reprogrammed cancer cell metabolism, remodeled extracellular matrix (ECM) and created a supportive niche for cancer stem cells. CAFs lead collective invasion of tumor cells and shape tumor immune microenvironment, promoting tumor metastasis and immune escape. In this review, we have summarized the progress of studies regarding CAFs influences on NSCLC in recent five years from the aspects of cell growth, metabolism, therapy resistance, invasion and metastasis and immune suppression. We have discussed the involved mechanisms and implications for the development of anti-NSCLC therapies. The current strategies of CAFs targeting and elimination have also been generalized. Only better understanding of the molecular biology of CAFs may contribute to the development of novel anti-NSCLC strategies.
Copyright © 2021. Published by Elsevier B.V.

Entities:  

Keywords:  Cancer-associated fibroblasts; Molecular mechanisms; Non-small cell lung cancer; Reversal strategies; Tumor-promoting activity

Mesh:

Year:  2021        PMID: 34019960     DOI: 10.1016/j.canlet.2021.05.009

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  7 in total

1.  Monocarboxylate Transporter 4 in Cancer-Associated Fibroblasts Is a Driver of Aggressiveness in Aerodigestive Tract Cancers.

Authors:  Marina Domingo-Vidal; Diana Whitaker-Menezes; Mehri Mollaee; Zhao Lin; Madalina Tuluc; Nancy Philp; Jennifer M Johnson; Tingting Zhan; Joseph Curry; Ubaldo Martinez-Outschoorn
Journal:  Front Oncol       Date:  2022-06-22       Impact factor: 5.738

2.  Construction of a prognostic immune-related lncRNA model and identification of the immune microenvironment in middle- or advanced-stage lung squamous carcinoma patients.

Authors:  Qianqian Xue; Yue Wang; Qiang Zheng; Lijun Chen; Yan Jin; Xuxia Shen; Yuan Li
Journal:  Heliyon       Date:  2022-05-23

3.  DHW-221, a Dual PI3K/mTOR Inhibitor, Overcomes Multidrug Resistance by Targeting P-Glycoprotein (P-gp/ABCB1) and Akt-Mediated FOXO3a Nuclear Translocation in Non-small Cell Lung Cancer.

Authors:  Mingyue Liu; Chang Xu; Xiaochun Qin; Wenwu Liu; Deping Li; Hui Jia; Xudong Gao; Yuting Wu; Qiong Wu; Xiangbo Xu; Bo Xing; Xiaowen Jiang; Hongyuan Lu; Yingshi Zhang; Huaiwei Ding; Qingchun Zhao
Journal:  Front Oncol       Date:  2022-05-13       Impact factor: 5.738

4.  A novel immune-related long non-coding RNAs risk model for prognosis assessment of lung adenocarcinoma.

Authors:  Songmei Lu; Nan Shan; Xingyue Chen; Fangliang Peng; Yiming Wang; Hao Long
Journal:  Aging (Albany NY)       Date:  2021-12-14       Impact factor: 5.682

5.  Treatment selection with organoids in an EGFRm + TP53m stage IA1 patient with recurrence after radical surgery.

Authors:  Yoshikane Yamauchi; Yuichi Saito
Journal:  J Thorac Dis       Date:  2022-03       Impact factor: 2.895

Review 6.  Cancer-Associated Fibroblasts: Mechanisms of Tumor Progression and Novel Therapeutic Targets.

Authors:  Ralf-Peter Czekay; Dong-Joo Cheon; Rohan Samarakoon; Stacie M Kutz; Paul J Higgins
Journal:  Cancers (Basel)       Date:  2022-02-27       Impact factor: 6.639

7.  Emerging insights to lung cancer drug resistance.

Authors:  Chunxia Su
Journal:  Cancer Drug Resist       Date:  2022-06-21
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.